CLINUVEL’s Managing Director (MD), Dr Philippe Wolgen, addresses questions received from shareholders and what lies ahead for the Company as we progress our commercial and clinical programs, with a particular focus on treating vitiligo patients with afamelanotide and narrowband UVB (NB-UVB).